Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. Meeting materials will be mailed following finalization and filing with the Securities and Exchange Commission (SEC), according to the company's press release.
In a separate disclosure, the company revealed that its 2025 annual report included an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm. The disclosure was made as required under Section 610(b) of the NYSE American Company Guide. The company emphasized that the going concern notice does not reflect any change or amendment to previously filed financial statements.
Kairos Pharma is based in Los Angeles, California, and is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, aimed at addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The going concern notice raises questions about the company's financial stability and its ability to continue operations. For investors, this disclosure is significant as it indicates potential risks in the company's future. The company's ability to secure additional funding or achieve milestones will be crucial for its survival and the advancement of its clinical programs.
The impact of this news extends to the broader biotech industry, as it highlights the financial challenges faced by clinical-stage companies developing novel therapies. Kairos Pharma's focus on overcoming drug resistance in cancer could have substantial implications if its treatments are successful, but the going concern notice underscores the financial hurdles that such companies often encounter before reaching commercialization.
For more details, the full press release is available at https://ibn.fm/sQ0pm.
